Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crinó L., Ahn M.J., De Pas T., Besse B., Solomon B.J., Blackhall F., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385-2394. doi: 10.1056/NEJMoa1214886..
DOI: 10.1056/NEJMoa1214886
Tsao A.S., Scagliotti G.V., Bunn P.A. Jr, Carbone D.P., Warren G.W., Bai C., et al. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016;11(5):613-638. DOI: 10.1016/j.jtho.2016.03.012..
DOI: 10.1016/j.jtho.2016.03.012
Novello S., Mazieres J., Oh I.J., de Castro J., Migliorino M.R., Helland A., et al. Primary Results from the Phase III ALUR Study of Alectinib versus Chemotherapy in Previously Treated ALK+Non-Small-Cell Lung Cancer (NSCLC). Annals of Oncology 2017;28(suppl_5):v605-v649. doi: 10.1093/annonc/mdx440.058..
DOI: 10.1093/annonc/mdx440.058
Kerr K.M., López-Ríos F. Precision medicine in NSCLC and pathology: how does ALK fit in the pathway? Ann Oncol. 2016;27(Suppl 3):iii16-iii24. doi: 10.1093/annonc/mdw302..
DOI: 10.1093/annonc/mdw302
Solomon B.J., Mok T., Kim D.W., Wu Y.L., Nakagawa K., Mekhail T., Felip E., Cappuzzo F., Paolini J., Usari T., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167-2177. doi: 10.1056/NEJMoa1408440..
DOI: 10.1056/NEJMoa1408440
Duruisseaux M., Besse B., Cadranel J., Pérol M., Mennecier B., Bigay-Game L., Descourt R., Dansin E., Audigier-Valette C., Moreau L., et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive nonsmall-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget. 2017;8(13):21903-21917. doi: 10.18632/oncotarget.15746..
DOI: 10.18632/oncotarget.15746
Peters S., Camidge D.R., Shaw A.T., Gadgeel S., Ahn J.S., Kim D.W. et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-SmallCell Lung Cancer. N Engl J Med. 2017;377(9):829-838. doi: 10.1056/NEJMoa1704795..
DOI: 10.1056/NEJMoa1704795
Shaw A.T., Gandhi L., Gadgeel S., Riely G. et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016;17(2):234-242. doi: 10.1016/S1470-2045(15)00488-X..
DOI: 10.1016/S1470-2045(15)00488-X
Ou S.H., Ahn J.S., De Petris L., Govindan R., Yang J.C., Hughes B., Lena H., Moro-Sibilot D., Bearz A., Ramirez S.V., et al. Alectinib in crizotinib-refractory ALK- rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol. 2016;34(7):661-668. doi: 10.1200/JCO.2015.63.9443..
DOI: 10.1200/JCO.2015.63.9443
Gadgeel S.M., Ganghi L., Riely G.J., Chiappori A.A., West H.L., Azada M.C. et al. Safety and activity of alectenib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer: results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014;15(10):1119-1128. doi: 10.1016/S1470-2045(14)70362-6..
DOI: 10.1016/S1470-2045(14)70362-6
Реутова Е.В., Лактионов К.К. Новые возможности в лечении больных ALK-позитивным немелкоклеточным раком легкого. Онкология. Журнал им. П.А. Герцена. 2019;8(3):226-230. doi: 10.17116/onkolog2019803115226..
DOI: 10.17116/onkolog2019803115226
Camidge D.R., Peters S., Mok T., Gadgeel S.M., Cheema P.K., Pavlakis N., Marinis F.D., Stroyakovskiy D.L., Cho B.C., Zhang L., et al. Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+NSCLC. ASCO 2018. Available at: https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.9043.https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.9043
Camidge D.R., Peters S., Mok T., Gadgeel S.M., Cheema P.K., Pavlakis N., Marinis F.D., Stroyakovskiy D.L., Cho B.C., Zhang L., et al. Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+NSCLC. ASCO 2018. Available at: https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.9043.https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.9043
Mok T.S.K., Shaw A.T., Camidge R.D., Gadgeel S.M., Rosell R., Dziadziuszko R., et al. Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC. Annals of Oncology. 2019;30(Suppl_5):mdz260.006. doi: 10.1093/annonc/mdz260.006..
DOI: 10.1093/annonc/mdz260.006